Astrana Health Reports Robust Q1 2026 Results with 56% Revenue Growth and Doubled Net Income

summarizeSummary

Astrana Health delivered strong first-quarter 2026 financial results, driven by the Prospect acquisition, with significant increases in revenue, adjusted EBITDA, and net income, alongside positive operating cash flow.

check_boxKey Events

• Strong Revenue Growth

  Total revenue increased 56% year-over-year to $965.1 million, primarily due to the Prospect acquisition and members transitioning to full risk through Restricted Knox-Keene plans.

• Doubled Net Income & EPS

  Net income attributable to Astrana Health, Inc. rose 116% to $14.4 million, with diluted earnings per share increasing to $0.29 from $0.14 in the prior year period.

• Significant Adjusted EBITDA Increase

  Adjusted EBITDA grew 82% to $66.3 million, reflecting strong operational performance, largely driven by the Prospect acquisition.

• Substantial Operating Cash Flow

  Net cash provided by operating activities surged 309% to $68.1 million, driven by favorable changes in working capital and higher adjusted net income.

auto_awesomeAnalysis

Astrana Health's Q1 2026 results demonstrate significant operational momentum, largely driven by the successful integration of the Prospect acquisition. The substantial growth in revenue, adjusted EBITDA, and net income, coupled with a strong increase in operating cash flow, indicates a healthy financial position and effective execution of its value-based care strategy. While the reiterated disclosure of a material weakness in internal controls remains a concern, the company's robust financial performance and positive outlook on Medicare Advantage rates suggest a strong trajectory. The increased share repurchase authorization also signals management's confidence and commitment to shareholder returns. Investors should monitor the remediation efforts for the material weakness, but the overall financial strength is a compelling positive.